Discover
MDGL
Madrigal Pharmaceuticals, Inc.
507.95
1 x 511.93
1 x 512.55
bid
ask
-
8.79
1.70%
11:06 AM
timesize
| Ytd | -12.77% | |
| 1y | 22.49% |
507.18
day range
517.00
393.61
52 week range
615.00
| Open | 517.00 | Prev Close | 516.74 | Low | 507.18 | High | 517.00 | Mkt Cap | 11.74B |
| Vol | 24.54K | Avg Vol | 363.11K | EPS | -13.97 | P/E | N/A | Forward P/E | 53.69 |
| Beta | -1.01 | Short Ratio | 5.41 | Inst. Own | 104.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 522.83 | 200-d Avg | 513.86 | 1yr Est | 678.06 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.86 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -2.68 | -1.99 | 0.69 | 25.75% |
| 2026-05-06 | 2026-03 | -3.61 | -3.25 | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | -2.57 | -2.61 | -6525.00% |
| 2025-11-04 | 2025-09 | -2.04 | -5.08 | -3.04 | -149.38% |
| 2025-08-05 | 2025-06 | -3.48 | -1.9 | 1.58 | 45.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-04 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| 2026-08-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-07-29 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-06-11 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-05-13 | Truist Securities | Upgrade | Buy | Buy |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Sale |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Sale |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-03-05 | KELLEY SHANNON T | General Counsel | 12.14K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Baker Bros. Advisors, LP | 2.14M | 1.11B | 9.28% |
| 2026-06-29 | RTW Investments LP | 1.99M | 1.03B | 8.63% |
| 2026-06-29 | Jupiter Topco LLC | 1.94M | 1.00B | 8.38% |
| 2026-06-29 | Avoro Capital Advisors LLC | 1.83M | 947.36M | 7.94% |
| 2026-06-29 | PAULSON & CO. INC. | 1.34M | 692.44M | 5.80% |
| 2026-06-29 | Blackrock Inc. | 1.20M | 620.49M | 5.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 586.33K | 302.98M | 2.54% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 423.15K | 218.66M | 1.83% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 408.92K | 211.30M | 1.77% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 338.60K | 174.97M | 1.47% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 236.63K | 122.28M | 1.02% |
| 2026-06-29 | JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 233.27K | 120.54M | 1.01% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |